iPierian, Inc.

Biopharmaceutical companies developing therapies for neurological diseases are in the midst of a boom, not only in terms of novel approaches to treating intractable diseases but also in terms of attra

Biogen will end development in progressive supranuclear palsy (PSP) and other primary tauopathies for gosuranemab (BIIB092) – an anti-tau antibody licensed from Bristol-Myers Squibb Co. in 2017 for

John Milligan is to stand down as CEO of Gilead Sciences Inc. at the end of the year. Former CEO and current chair John Martin will also stand down upon the appointment of a new CEO. Milligan

Biogen Inc. plans to move quickly to study its new tau antibody in Phase II clinical trials in Alzheimer's disease and progressive supranuclear palsey (PSP) after licensing it from Bristol-Myers S